SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Bright Mountain Media's borrower entity received lender approval to dispose of the Mom.com domain name and social media handles to Static Media, Inc. for $1.1 million in net cash p…
The FDA approved Rextovy, a 4mg naloxone hydrochloride nasal spray available over-the-counter for emergency opioid overdose treatment. This approval expands patient access to nalox…
Oncolytics Biotech announced a newly issued USPTO patent protecting its proprietary manufacturing process for pelareorep, providing intellectual property protection until 2044. The…
Kennedy-Wilson Holdings filed its Third Amended and Restated Certificate of Incorporation with the SEC, authorizing 200M common shares and 1M preferred shares. The filing reflects …
Outlook Therapeutics announced FDA acceptance of its resubmitted Biologics License Application for ONS-5010/LYTENAVA (bevacizumab-vikg) as a treatment for wet AMD, with a PDUFA tar…
Palvella Therapeutics amended its 2024 Equity Incentive Plan to increase available shares for issuance to 4,090,639 shares, approved by stockholders on June 10, 2026. The increase …
Cingulate Inc. announced the issuance of U.S. Patent No. 12,653,791 for its lead ADHD asset CTx-1301, protecting the drug's formulation and method of use through December 2042. The…
Azitra increased total authorized shares from an unstated prior amount to 760M shares, comprising 750M common shares and 10M preferred shares. The amendment provides greater flexib…
SEA Craft LLC received regulatory approval on June 5, 2026 to restart cultivation operations at the Dwight, Illinois facility, with first harvest expected in September 2026. This e…
Monro released its 2026 ESG report emphasizing guest experience, teammate development, and climate reporting initiatives including first-time Scope 1 and 2 emissions measurement. T…
Acumen Pharmaceuticals nominated ACU301 and ACU401 as development candidates combining its amyloid beta oligomer antibodies with JCR Pharmaceuticals' blood-brain barrier penetratio…
Avalo Therapeutics announced advancement of AVTX-010, a next-generation anti-IL-1β monoclonal antibody designed for hidradenitis suppurativa and other inflammatory disorders, with …
HCW Biologics announced positive preliminary results from its Phase 1 clinical trial of HCW9302, with all three patients in the second dose cohort showing ≥25% improvement in alope…
Lifeloc Technologies completed production mold for SpinDetect drug analyzer test disks and commissioned a cleanroom facility to move the program into validation and early productio…
The FDA granted accelerated approval to Tzield (teplizumab) on June 12, 2026, for a new indication to delay insulin production decline in pediatric patients aged 8-17 with recently…
Encore Capital Group amended its certificate of incorporation to expand protections limiting personal liability of directors and officers for breach of fiduciary duty. The change p…
Dauch Corporation's represented workforce at its Three Rivers Manufacturing Facility in Michigan has ratified a new four-year collective bargaining agreement, with workers returnin…
Vistagen completed the randomized portion of its PALISADE-4 Phase 3 trial evaluating fasedienol for acute social anxiety disorder treatment, with results expected this month. The c…
Independent valuation advisor Altus Group U.S. Inc. consented to references regarding its role in the May 31, 2026 NAV per share valuation process for Ares Industrial Real Estate I…
Northann Corp. has received formal notice from NYSE American that it regained compliance with all continued listing standards, resolving a stockholders' equity deficiency disclosed…